16 results about "E Antigens" patented technology

The invention discloses an anti-human hepatitis B e antigen monoclonal antibody and application thereof, and relates to the technical field of hepatitis B detection. In a heavy chain variable region of the monoclonal antibody, an amino acid sequence of a complementarity determining region CDR1-3 is as shown in SEQ ID NO.1-3 or has at least 95% of homology with the sequence as shown in SEQ ID NO.1-3; in the light chain variable region, amino acid sequences of complementary determining regions CDR1 and CDR3 are shown as SEQ ID NO.4 and SEQ ID NO.5 or have at least 95% of homology with the sequences shown as SEQ ID NO.4 and SEQ ID NO.5, and an amino acid sequence of a complementary determining region CDR2 is FAS. The monoclonal antibody provided by the invention can well recognize a natural hepatitis B e antigen, and the titer of a supernatant cultured by a B cell can reach 1: 10000, so that the monoclonal antibody can be completely applied to detection research of the human hepatitis B e antigen. The chemiluminescence reagent prepared by using the monoclonal antibody has the advantages of high specificity, strong anti-interference capability, high detection sensitivity, good stability and the like, almost has no leak detection, and can replace an imported reagent.

This invention discloses a monoclonal antibody against human hepatitis B e antigen and its application, relating to the field of hepatitis B detection technology. In the heavy chain variable region of the monoclonal antibody, the amino acid sequences of the complementarity-determining regions (CDR1-3) are as shown in SEQ ID NO. 1-3 or have at least 95% homology with the sequences shown in SEQ ID NO. 1-3; in the light chain variable region, the amino acid sequences of the complementarity-determining regions (CDR1 and CDR3) are as shown in SEQ ID NO. 4 and 5 or have at least 95% homology with the sequences shown in SEQ ID NO. 4 and 5, and the amino acid sequence of the complementarity-determining region (CDR2) is FAS. The monoclonal antibody provided by this invention can effectively recognize natural hepatitis B e antigen, and the titer of the supernatant from B cell culture can reach 1:10000, making it fully applicable to the detection and research of human hepatitis B e antigen. The chemiluminescent reagent prepared using the monoclonal antibody described in this invention has advantages such as high specificity, strong anti-interference ability, high detection sensitivity, and good stability, with almost no missed detections, and can replace imported reagents.

A preparation method for and the use of an aluminum hydroxide oxide nano-adjuvant based on calcium and silicon doping. The particle morphology of the AlOOH adjuvant is a 50-800 nm nano-particle, wherein silicon or calcium is doped in AlOOH crystal lattices, and the molar ratio of calcium or silicon to aluminum is 0.01-100:1. The preparation method comprises: synthesizing AlOOH by using an Al source, doping Ca or Si in a reaction solution by using a calcium source or a silicon source, precipitating Al(OH)3 and a dopant by adding an alkaline solution, and preparing a Ca- or Si-doped AlOOH adjuvant by means of a hydrothermal synthesis method. In a hepatitis B surface antigen and varicella-zoster virus glycoprotein E antigen model, the calcium- or silicon-doped AlOOH nano-adjuvant can simultaneously induce efficient humoral immunity and cellular immunity by means of in-vivo experiment verification of mice.

The present disclosure relates to methods for increasing cell-mediated immunity against varicella zoster virus (VZV) in a human subject in need thereof by administration of an immunogenic composition comprising effective amounts of a VZV glycoprotein E antigen and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for prevention of herpes zoster and / or postherpetic neuralgia.

The invention relates to the field of in-vitro diagnosis immunodetection, in particular to a helicobacter pylori antibody typing detection test strip and a kit. The helicobacter pylori antibody typing detection test strip comprises a bottom plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad, and the sample pad, the combination pad, the nitrocellulose membrane and the water absorption pad are sequentially overlapped and pasted on the bottom plate in the chromatography direction; the nitrocellulose membrane is coated with three detection lines and one quality control line; the first detection line is coated with a Urease antigen, the second detection line is coated with a CagA antigen, the third detection line is coated with a VacA antigen, and the quality control line is coated with rabbit anti-DNP-BSA or goat anti-chicken IgY; the combination pad is coated with a biotinylation ProteinA / G-antibody marked by colored microspheres, and a biotinylation antibody or antigen marked by colored microspheres; the invention discloses a helicobacter pylori antibody typing detection test strip and a kit, which are good in stability and higher in sensitivity compared with similar products.

The present disclosure relates to a ribavirin derivative-embedded double-stranded siRNA analogue, a conjugate comprising the same, and salts and uses thereof. The double-stranded siRNA analogue, the conjugate comprising the same, and the salts thereof of the present disclosure can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, E antigen, etc., and provide an effective and feasible method for the treatment of hepatitis B.

The present disclosure relates to a method for increasing cell-mediated immunity against Varicella-Zoster Virus (VZV) in a human subject in need thereof by administration of an immunogenic composition comprising an effective amount of a VZV glycoprotein E antigen and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic composition is suitable for the prevention of varicella zoster and / or post-herpetic neuralgia.

To provide pluripotent cells including induced pluripotent stem cell, embryonic stem cells and hypo-immune pluripotent cells that are ABO blood type O Rhesus Factor negative and evade rejection resulting from blood type antigen mismatch.SOLUTION: Provided is a modified pluripotent cell or a cell derived therefrom where the cell is ABO blood type O Rhesus Factor negative (Rh-), and the cell has: (a) reduced or eliminated ABO blood type antigen selected from the group consisting of A1, A2 and B; and / or (b) reduced or eliminated expression of Rh protein antigen selected from the group consisting of Rh C antigen, Rh E antigen, Kell K antigen (KEL), Duffy (FY) Fya antigen, Duffy Fy3 antigen, Kidd(JK), Jkb antigen, MNS antigen U and MNS antigen S.SELECTED DRAWING: None

The application discloses a monoclonal antibody against hepatitis B virus e antigen and a preparation method and application thereof, and relates to the field of hepatitis B antigen detection. Specifically, the antibody provided by the application has HCDR1-3 as shown in SEQ ID NO: 1, 2 and 3 respectively, and LCDR1-3 as shown in SEQ ID NO: 4, 5 and 6 respectively. The provided antibody can specifically recognize human hepatitis B e antigen. The positive coincidence rate, the negative coincidence rate and the total coincidence rate of a detection reagent constructed using the antibody and the Abbott control reagent are all 100%. Compared with an existing antibody 3A3, the stability and the repeatability of detection are significantly improved, and the early detection rate of the reagent kit has important value.

This application discloses a chimeric antigen comprising dengue virus NS5 antigen and E antigen. Specifically, this application relates to a chimeric antigen, a nucleic acid molecule, an expression vector, a host cell, reagents, a kit, and its uses. The chimeric antigen of this application, or its conjugates, possesses enhanced activity and can be used to prepare kits for accurate detection of antibodies against dengue virus.

Provided are a ribavirin derivative-embedded double-stranded siRNA analog, a conjugate comprising the same, and a salt and use thereof. The provided double-stranded siRNA analog, the conjugate comprising the same, and the salt thereof can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, E antigen, etc., and provide an effective and feasible method for the treatment of hepatitis B.

The present disclosure relates to immunogenic compositions comprising a varicella zoster vims (VZV) glycoprotein E antigen and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against VZV in an individual in need thereof.

The present invention provides immunogenic compositions, kits, and methods suitable for stimulating an immune response to varicella-zoster virus (VZV) in individuals requiring such stimulation. [Solution] An immunogenic composition is provided comprising varicella-zoster virus (VZV) glycoprotein E antigen and a Toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide containing a non-methylated cytidine-phospho-guanosine (CpG) motif.

The invention provides a spectrum cell composition as well as a preparation method and application thereof. The cell composition comprises the following blood group system antigens: D, C, c, E and e antigens of an Rh system; a Jka antigen and a Jkb antigen of a Kidd system; m, N, S, s and Mur antigens of an MNS system; an Fya antigen and an Fyb antigen of the Duffy system; a Dia antigen and a Dib antigen of a Diego system; a K, k antigen of the Kell system; a Lea antigen and a Leb antigen of the Lewis system; a P1 antigen of the P system; and Doa and Dob antigens of a Do system. The spectrum cell composition provided by the invention can more accurately identify the Mur antibody, and also considers detection of other common antibodies, so that hemolytic reaction caused by missing detection of the antibody of a blood transfusion patient is avoided, the problem of missing detection of the Mur antibody is effectively solved, and blood transfusion safety is better guaranteed.

The invention discloses oligonucleotide of targeted RNA (Ribonucleic Acid) binding protein SND1 and application of the oligonucleotide, and belongs to the field of biological medicines. The nucleotide sequence of the oligonucleotide of the targeted RNA binding protein SND 1 disclosed by the invention is selected from SEQ ID NO.1-3. The invention discovers that SND1 protein is related to HBV replication for the first time, and verifies that the oligonucleotide of the targeted RNA binding protein SND1 can significantly inhibit the levels of HBV DNA, Total RNA, pgRNA, S protein, HBV antigen S and E antigen while significantly inhibiting the expression of SND1 RNA and protein, and finally improves or treats HBV. The invention has important significance for developing novel anti-HBV drugs, and has wide prospect and huge economic value.